HPV Vaccination in HIV Infected and HIV Uninfected Adolescents in Eswatini

PHASE4CompletedINTERVENTIONAL
Enrollment

1,403

Participants

Timeline

Start Date

April 1, 2022

Primary Completion Date

December 9, 2024

Study Completion Date

December 9, 2024

Conditions
HPV InfectionHivHPV Vaccine
Interventions
BIOLOGICAL

Gardasil ® 9

"GARDASIL 9 is a vaccine indicated in girls and women 9 through 45 years of age for the prevention of the following diseases: Cervical, vulvar, vaginal, and anal cancer, and Genital warts (condyloma acuminata) caused by Human Papillomavirus (HPV).~0.5-mL suspension for intramuscular injection as a single-dose vial and prefilled syringe at the following regimen/schedule: 9 through 14 years - 2-dose at 0, 6 to 12 months OR 3-dose at 0, 2, 6 months 15 through 45 years - 3-dose at 0, 2, 6 months"

Trial Locations (5)

Unknown

AHF Lamvelase, Manzini

AHF Manzini, Manzini

Raleigh Fitkin Memorial Hospital, Manzini

AHF Matsapha, Matsapha

Baylor College of Medicine - Bristol Myers-Squibb Children's Clinical Centre of Excellence, Mbabane

All Listed Sponsors
collaborator

Jhpiego

OTHER

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Columbia University

OTHER